Cancer Treatment Services International (CTSI), a wholly owned subsidiary of Varian Medical Systems Inc (a Siemens Healthineers Company), has announced the appointment of Harish Trivedi, as the Chief Executive Officer- CTSI South Asia network effective 20th March 2023.
In this capacity Harish will be responsible for steering the operations of American Oncology Institute (Cancer Treatment Services Hyderabad Pvt. Ltd.), Citizens Specialty Hospital (Artmed Healthcare Pvt. Ltd.) and Ampath (American Institute of Pathology and Laboratory Sciences Pvt. Ltd.) in the Indian Subcontinent. Harish will be based out of Hyderabad Corporate Office and will be reporting to Dr Jagprag Singh Gujral, SVP MDO / Head of Emerging Markets, Group CEO CTSI.
Speaking on the senior leadership role, Dr Jagprag Singh Gujral, SVP MDO / Head of Emerging Markets, Group CEO CTSI said, “On behalf of the CTSI South Asia family and the Varian (a Siemens Healthineers Company) leadership, we are delighted to welcome Harish Trivedi as the new CEO on board. His experience would be greatly valued in providing strategic direction and delivering long-term strategic growth plans along with day-to-day management decisions for the organization. He will play a major role at CTSI as we continue to expand and maintain momentum in home markets whilst strengthening our presence across South Asia.”
With over 25+ years of rich healthcare experience, Harish Trivedi will be responsible for driving and overseeing the development and execution of the hospital’s strategy, quality excellence, and patient relationship management.
Harish transitioned to healthcare delivery over the last decade and has had accomplished healthcare stints with Fortis Healthcare, Max Healthcare and Apollo Hospitals, where he has been instrumental in strategizing and restructuring key functions. He holds a master’s degree in management from the University of Mumbai with an impressive track record in various industries (like General Mills, Pepsico, Tata Tele and Reliance Retail).
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
Merck partners with California-based research group to study catalysis innovation through machine learning
Philips and Masimo introduce advanced monitoring capabilities to Philips high acuity patient monitors
Subscribe To Our Newsletter & Stay Updated